GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
|
GILD announced that the investigational single-tablet
regimen of bictegravir and lenacapavir for the treatment of HIV met
the primary endpoint in the ... |
40 Million People Affected as HIV Cure Research Takes Big Step Forward
More than 40.8 million people worldwide were living with HIV in 2024, and 1.3 million were newly infected that year, according to the latest ... View article...